Johnson & Johnson Showcases Neuropsychiatry Data at APA 2026
TITUSVILLE, N.J., May 11, 2026 Johnson & Johnson announced the presentation of 18 new and encore abstracts highlighting the...
Lumateperone
Advertisement
Johnson & Johnson Highlights CAPLYTA Superiority in MDD Study
TITUSVILLE, NEW JERSEY, May 04, 2026 Johnson & Johnson has announced new findings demonstrating that CAPLYTA® (lumateperone) achieved the...
Johnson & Johnson Strengthens CNS Portfolio with CAPLYTA FDA Nod
TITUSVILLE, NEW JERSEY, April 27, 2026 Johnson & Johnson has received U.S. Food and Drug Administration (FDA) approval for...
FDA Clears CAPLYTA® as New Adjunctive Therapy for Depression
Titusville, New Jersey – November 6, 2025 – Johnson & Johnson (NYSE: JNJ) announced that the U.S. Food and...
Advertisement
